Published in Infect Immun on December 08, 2014
The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol (2015) 1.34
Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J (2017) 0.83
Human Periodontal Stem Cells Release Specialized Proresolving Mediators and Carry Immunomodulatory and Prohealing Properties Regulated by Lipoxins. Stem Cells Transl Med (2015) 0.81
Therapeutic Targets for Management of Periodontitis and Diabetes. Curr Pharm Des (2016) 0.79
High ω3-polyunsaturated fatty acids in fat-1 mice prevent streptozotocin-induced Purkinje cell degeneration through BDNF-mediated autophagy. Sci Rep (2015) 0.79
Activation and resolution of periodontal inflammation and its systemic impact. Periodontol 2000 (2015) 0.79
Resolvin E1 Reverses Experimental Periodontitis and Dysbiosis. J Immunol (2016) 0.78
Relationship between glycemic control and histochemical myeloperoxidase activity in neutrophils in patients with type 2 diabetes. Diabetol Metab Syndr (2015) 0.77
Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer. World J Clin Cases (2016) 0.76
Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes. J Immunol (2016) 0.75
Interleukin-1 and estrogen protect against disseminating dentoalveolar infections. Int J Oral Sci (2017) 0.75
Pro-resolving mediators in the regulation of periodontal disease. Mol Aspects Med (2017) 0.75
FOXO1 Regulates Bacteria-Induced Neutrophil Activity. Front Immunol (2017) 0.75
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol (2008) 11.02
Nonresolving inflammation. Cell (2010) 7.74
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res (2012) 5.57
Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov (2004) 5.08
Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med (2005) 5.00
Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation (2005) 4.17
Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care (1993) 3.71
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60
Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32
Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27
Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J (2009) 2.83
Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol (2007) 2.83
Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol (2008) 2.82
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol (2007) 2.66
RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J (2005) 2.47
Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol (2010) 2.16
A novel mouse model to study the virulence of and host response to Porphyromonas (Bacteroides) gingivalis. Infect Immun (1991) 2.07
Diabetes-obesity syndromes in mice. Diabetes (1982) 2.01
Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One (2010) 1.95
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest (2011) 1.92
Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. J Periodontol (1996) 1.90
Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J (2011) 1.72
Periodontitis and diabetes interrelationships: role of inflammation. Ann Periodontol (2001) 1.58
Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med (1999) 1.55
Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem (2009) 1.50
Evidence of polymorphonuclear neutrophils (PMN) activation in patients with insulin-dependent diabetes mellitus. J Leukoc Biol (1987) 1.38
Atherosclerosis: the new view. Sci Am (2002) 1.36
Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol (2012) 1.31
Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1. PLoS One (2011) 1.29
Diabetic complications and dysregulated innate immunity. Front Biosci (2008) 1.28
The management of inflammation in periodontal disease. J Periodontol (2008) 1.26
Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep (2008) 1.23
Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J Leukoc Biol (2008) 1.19
Hyperinsulinemia in pre-weaning diabetes (db) mice. Diabetologia (1974) 1.16
Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions. Invest Ophthalmol Vis Sci (2009) 1.15
Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm Bowel Dis (2010) 1.13
An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br J Pharmacol (2008) 1.13
Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse. Ann Rheum Dis (1986) 1.12
Diabetes aggravates periodontitis by limiting repair through enhanced inflammation. FASEB J (2011) 1.09
Role of superoxide dismutase in resistance of Porphyromonas gingivalis to killing by polymorphonuclear leukocytes. Infect Immun (1992) 1.08
Resistance of a Tn4351-generated polysaccharide mutant of Porphyromonas gingivalis to polymorphonuclear leukocyte killing. Infect Immun (1995) 1.07
Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. Curr Pharm Des (2009) 1.06
Chronic hyperglycemia predisposes to exaggerated inflammatory response and leukocyte dysfunction in Akita mice. J Immunol (2006) 1.02
Natural resolution of inflammation. Periodontol 2000 (2013) 0.97
Hemoglobin A1c levels among patients with diabetes receiving nonsurgical periodontal treatment. JAMA (2014) 0.97
Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol (2012) 0.92
B lymphocytes in human subcutaneous adipose crown-like structures. Obesity (Silver Spring) (2012) 0.92
Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. Annu Rev Pathol (2007) 0.89
Zinc deficiency augments leptin production and exacerbates macrophage infiltration into adipose tissue in mice fed a high-fat diet. J Nutr (2013) 0.84
A murine intraperitoneal infection model reveals that host resistance to Campylobacter jejuni is Nramp1 dependent. Microbes Infect (2008) 0.82
Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury through ChemR23. EMBO Rep (2013) 0.81
The influence of diabetes mellitus on periodontal tissues: a pilot study. J Periodontal Implant Sci (2010) 0.80
The role of coaggregation between Porphyromonas gingivalis and Fusobacterium nucleatum on the host response to mixed infection. J Clin Periodontol (2012) 0.79
Platelet-neutrophil conjugate formation is increased in diabetic women with cardiovascular disease. Cardiovasc Diabetol (2003) 0.78
Effective in vitro clearance of Porphyromonas gingivalis by Fc alpha receptor I (CD89) on gingival crevicular neutrophils. Infect Immun (2001) 0.77
Resolvin E1 as a novel agent for the treatment of asthma. Expert Opin Ther Targets (2009) 0.76